ES2189768T3 - Sintesis regioselectiva de derivados de rapamicina. - Google Patents

Sintesis regioselectiva de derivados de rapamicina.

Info

Publication number
ES2189768T3
ES2189768T3 ES00966904T ES00966904T ES2189768T3 ES 2189768 T3 ES2189768 T3 ES 2189768T3 ES 00966904 T ES00966904 T ES 00966904T ES 00966904 T ES00966904 T ES 00966904T ES 2189768 T3 ES2189768 T3 ES 2189768T3
Authority
ES
Spain
Prior art keywords
regional
rapamycin
rapamycin derivatives
silyl ether
elementary synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00966904T
Other languages
English (en)
Spanish (es)
Inventor
Chia-Cheng Shaw
John Hamilton Sellstedt
Razzak Noureldin
Gloria Karen Cheal
Genevieve Fortier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Application granted granted Critical
Publication of ES2189768T3 publication Critical patent/ES2189768T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES00966904T 1999-09-29 2000-09-27 Sintesis regioselectiva de derivados de rapamicina. Expired - Lifetime ES2189768T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40883099A 1999-09-29 1999-09-29

Publications (1)

Publication Number Publication Date
ES2189768T3 true ES2189768T3 (es) 2003-07-16

Family

ID=23617953

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00966904T Expired - Lifetime ES2189768T3 (es) 1999-09-29 2000-09-27 Sintesis regioselectiva de derivados de rapamicina.

Country Status (24)

Country Link
EP (1) EP1216251B1 (enExample)
JP (1) JP4289813B2 (enExample)
KR (1) KR100754236B1 (enExample)
CN (1) CN1176925C (enExample)
AR (1) AR029181A1 (enExample)
AT (1) ATE233269T1 (enExample)
AU (1) AU782234B2 (enExample)
BR (1) BR0014433A (enExample)
CA (1) CA2385461C (enExample)
CZ (1) CZ300368B6 (enExample)
DE (1) DE60001510T2 (enExample)
DK (1) DK1216251T3 (enExample)
EA (1) EA004331B1 (enExample)
ES (1) ES2189768T3 (enExample)
HK (1) HK1044774B (enExample)
HU (1) HUP0202609A3 (enExample)
IL (2) IL148542A0 (enExample)
MX (1) MXPA02003243A (enExample)
NO (1) NO20021360L (enExample)
NZ (1) NZ517644A (enExample)
PL (1) PL200899B1 (enExample)
TW (1) TWI256395B (enExample)
WO (1) WO2001023395A2 (enExample)
ZA (1) ZA200201918B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
AU2004270154A1 (en) 2003-09-03 2005-03-17 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
AR046194A1 (es) 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
EP1737869A1 (en) * 2004-04-14 2007-01-03 Wyeth a Corporation of the State of Delaware Regiospecific synthesis of rapamycin 42-ester derivatives
CA2564811A1 (en) 2004-04-14 2005-10-27 Wyeth Proline cci-779 (proline-rapamycin 42-ester with 2,2-bis (hydroxymethyl) propionic acid) and two-step enzymatic synthesis of proline cci-779 and cci-779 using microbial lipase
SV2006002188A (es) 2004-08-10 2006-03-15 Wyeth Corp Derivados de cci - 779 y metodos para su preparacion ref. am-101759salvo
CN108421044A (zh) 2005-02-03 2018-08-21 综合医院公司 治疗吉非替尼耐药性癌症的方法
EP1856130A1 (en) 2005-02-09 2007-11-21 Wyeth a Corporation of the State of Delaware Cci-779 polymorph and use thereof
BRPI0618042A2 (pt) 2005-11-04 2011-08-16 Wyeth Corp usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN102641270A (zh) 2008-06-17 2012-08-22 惠氏有限责任公司 含有hki-272和长春瑞滨的抗肿瘤组合
CN101676291B (zh) 2008-09-18 2012-05-09 上海海和药物研究开发有限公司 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途
AU2011210227A1 (en) * 2010-01-28 2012-08-30 Fresenius Kabi Oncology Ltd. Process for the preparation of Temsirolimus and its intermediates
CN102020662B (zh) 2011-01-07 2013-02-13 天津市炜杰科技有限公司 一种驮瑞塞尔制备方法
EP2694520A1 (en) * 2011-04-01 2014-02-12 Sandoz AG Regioselective acylation of rapamycin at the c-42 position
CN103421023B (zh) * 2013-07-30 2015-09-23 福建省微生物研究所 一种替西罗莫司的合成工艺
CN104086564B (zh) * 2014-07-30 2019-02-05 江苏奥赛康药业股份有限公司 一种高纯度坦罗莫司的制备方法
CN106146536B (zh) * 2015-04-25 2019-07-26 山东新时代药业有限公司 一种依维莫司的制备方法
CA3017690C (en) * 2016-03-14 2024-02-20 Wisconsin Alumni Research Foundation Oligolactic acid conjugates and micelles with enhanced anticancer efficacy
CN107561170B (zh) * 2016-07-02 2021-07-30 山东新时代药业有限公司 一种坦西莫司中间体的分析检测方法
CN108948046B (zh) * 2017-05-20 2020-11-10 鲁南制药集团股份有限公司 一种替西罗莫司的中间体及其制备方法
CN108948045A (zh) * 2017-05-20 2018-12-07 鲁南制药集团股份有限公司 一种替西罗莫司的制备方法
CN109206441B (zh) * 2017-06-30 2022-05-20 正大天晴药业集团股份有限公司 一种依维莫司的纯化方法
CN109776570A (zh) * 2017-11-14 2019-05-21 上海医药工业研究院 一种依维莫司中间体、其制备方法及其应用
IL314362A (en) 2018-06-15 2024-09-01 Janssen Pharmaceutica Nv Rapamycin analogs and their uses
CN109369679A (zh) * 2018-12-24 2019-02-22 江苏卓和药业有限公司 一种雷帕霉素的精制方法
CN109851626B (zh) * 2019-01-08 2021-11-02 扬子江药业集团四川海蓉药业有限公司 一种替西罗莫司的分离纯化方法
BR112022010754A2 (pt) 2019-12-05 2022-08-23 Anakuria Therapeutics Inc Análogos de rapamicina e usos dos mesmos
CN113372359A (zh) * 2020-03-10 2021-09-10 鲁南制药集团股份有限公司 一种坦西莫司的制备方法
CN114106014B (zh) * 2020-08-27 2024-03-15 鲁南制药集团股份有限公司 一种依维莫司的制备方法
CN115028658A (zh) * 2022-07-06 2022-09-09 国药集团川抗制药有限公司 雷帕霉素硅醇酯及其制备方法和应用
GB202415232D0 (en) 2024-10-16 2024-11-27 Nacamed As Composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120842A (en) * 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5387680A (en) * 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines

Also Published As

Publication number Publication date
NZ517644A (en) 2003-09-26
EA004331B1 (ru) 2004-04-29
EA200200412A1 (ru) 2002-10-31
DE60001510T2 (de) 2003-10-02
JP4289813B2 (ja) 2009-07-01
HUP0202609A2 (hu) 2002-12-28
HK1044774A1 (en) 2002-11-01
ATE233269T1 (de) 2003-03-15
ZA200201918B (en) 2003-08-27
BR0014433A (pt) 2002-06-11
DK1216251T3 (da) 2003-06-16
IL148542A (en) 2006-08-20
MXPA02003243A (es) 2002-09-30
AU782234B2 (en) 2005-07-14
NO20021360D0 (no) 2002-03-19
WO2001023395A3 (en) 2001-10-25
AU7718200A (en) 2001-04-30
CA2385461C (en) 2009-03-17
TWI256395B (en) 2006-06-11
EP1216251B1 (en) 2003-02-26
DE60001510D1 (de) 2003-04-03
CA2385461A1 (en) 2001-04-05
AR029181A1 (es) 2003-06-18
HUP0202609A3 (en) 2004-11-29
CN1176925C (zh) 2004-11-24
JP2003510329A (ja) 2003-03-18
KR20020029796A (ko) 2002-04-19
IL148542A0 (en) 2002-09-12
CN1402731A (zh) 2003-03-12
PL354461A1 (en) 2004-01-12
CZ20021136A3 (cs) 2002-06-12
PL200899B1 (pl) 2009-02-27
CZ300368B6 (cs) 2009-05-06
NO20021360L (no) 2002-03-19
HK1044774B (en) 2003-05-30
EP1216251A2 (en) 2002-06-26
KR100754236B1 (ko) 2007-09-03
WO2001023395A2 (en) 2001-04-05

Similar Documents

Publication Publication Date Title
ES2124373T3 (es) Procedimiento para la preparacion de derivados del acido n-acil-n,n',n'-etilendiamintriacetico.
SV1996000026A (es) Benzociclopentano oxazolidinonas que contienen heteroatomos
BR9906287A (pt) Bactéria pertencente ao gênero escherichia e que tem uma capacidade para produzir um l-aminoácido, e, processo para produzir um l-aminoácido
BR0111206A (pt) Derivados de arilmetilamina para uso como inibidores de triptase
BRPI0010891A (pt) geração de microespuma terapêutica.
BR0011489A (pt) Composições formadoras de pelìcula compreendendo amidos modificados e iota-carragenano e processos para a fabricação de cápsulas macias usando as mesmas
IL147184A0 (en) Substituted benzimidazole
ZA89233B (en) Topical metronidazole formulations and therapeutic uses thereof
BR0015622A (pt) Processo de limpeza que utiliza ondas ultra-sÈnicas
ZA9710796B (en) Oxyiminopregnanecarbolactones.
PT1109812E (pt) Pirrolobenzodiazepinas
BR0110751A (pt) Dispositivo
AR079399A2 (es) Procedimientos para preparar bifenazato
ES2192680T3 (es) Nuevos derivados de vitamina d con sustituyentes carbo- o heterociclicos en c-25, procedimiento para su preparacion, productos intermedios y la utilizacion para la preparacion de medicamentos.
NO20032371L (no) Makrolidsolvater
MY117381A (en) Use of 1-hydroxy-2-pyridone for the treatment of seborrheic dermatitis
MXPA03001081A (es) Medicamento anti-inflamatorio.
NO20023276D0 (no) Fremgangsmåte til å fremstille betulinsyre
YU5893A (sh) Sulfonilkarbamid i postupak za njegovo dobijanje
YU13499A (sh) Primena 1-hidroksi-2-piridona za lečenje seboroitičnog dermatitisa
ES2134184T3 (es) Empleo de etisterona para el tratamiento topico del acne o de la alopecia androgenetica.
AR022017A1 (es) Un agente para tratar el trastorno de la funcion de las celulas visuales. el metodo de tratamiento y el uso de dicho agente para la produccion de unacomposicion farmaceutica
ES2166800T3 (es) Procedimiento para la preparacion de o,s-acetales de 2,2-difluoroceteno sililo y o,s-esteres del acido alfa,alfa-difluoro-beta-sililoxi-1,3-dioxolan-4-propanoico.
NZ510116A (en) Tricyclic delta-3-piperidines as pharmaceuticals
BR0013799A (pt) Processo para a preparação de um composto, e, composto